These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26521988)

  • 21. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
    Karp JE; Garrett-Mayer E; Estey EH; Rudek MA; Smith BD; Greer JM; Drye DM; Mackey K; Dorcy KS; Gore SD; Levis MJ; McDevitt MA; Carraway HE; Pratz KW; Gladstone DE; Showel MM; Othus M; Doyle LA; Wright JJ; Pagel JM
    Haematologica; 2012 Nov; 97(11):1736-42. PubMed ID: 22733022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
    Ikezoe T; Ando K; Onozawa M; Yamane T; Hosono N; Morita Y; Kiguchi T; Iwasaki H; Miyamoto T; Matsubara K; Sugimoto S; Miyazaki Y; Kizaki M; Akashi K
    Cancer Sci; 2022 Dec; 113(12):4258-4266. PubMed ID: 35689544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
    Tan AR; Swain SM
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):77-85. PubMed ID: 12138401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
    Lee DJ; Zeidner JF
    Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
    [No Abstract]   [Full Text] [Related]  

  • 25. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS; Byrd JC; Grever M
    Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Flavopiridol, a cyclin-dependent kinase inhibitor].
    Lansiaux A; Bailly C
    Bull Cancer; 2000 Oct; 87(10):697-701. PubMed ID: 11084532
    [No Abstract]   [Full Text] [Related]  

  • 27. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
    Lyle L; Daver N
    Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
    Senderowicz AM
    Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
    Holkova B; Supko JG; Ames MM; Reid JM; Shapiro GI; Perkins EB; Ramakrishnan V; Tombes MB; Honeycutt C; McGovern RM; Kmieciak M; Shrader E; Wellons MD; Sankala H; Doyle A; Wright J; Roberts JD; Grant S
    Clin Cancer Res; 2013 Apr; 19(7):1873-83. PubMed ID: 23515411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
    Karp JE; Smith BD; Resar LS; Greer JM; Blackford A; Zhao M; Moton-Nelson D; Alino K; Levis MJ; Gore SD; Joseph B; Carraway H; McDevitt MA; Bagain L; Mackey K; Briel J; Doyle LA; Wright JJ; Rudek MA
    Blood; 2011 Mar; 117(12):3302-10. PubMed ID: 21239698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.
    Nelson DM; Joseph B; Hillion J; Segal J; Karp JE; Resar LM
    Leuk Lymphoma; 2011 Oct; 52(10):1999-2006. PubMed ID: 21728742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
    Bright SA; Campiani G; Deininger MW; Lawler M; Williams DC; Zisterer DM
    Biochem Pharmacol; 2010 Jul; 80(1):31-8. PubMed ID: 20206141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
    Bible KC; Kaufmann SH
    Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials referral resource. Flavopiridol.
    Colevas D; Blaylock B; Gravell A
    Oncology (Williston Park); 2002 Sep; 16(9):1204-5, 1210-2, 1214. PubMed ID: 12380947
    [No Abstract]   [Full Text] [Related]  

  • 35. Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia.
    Jones JA; Kraut EH; Deam D; Byrd JC; Grever MR
    Leuk Lymphoma; 2012 Mar; 53(3):490-1. PubMed ID: 22165992
    [No Abstract]   [Full Text] [Related]  

  • 36. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
    Song Y; Shen K; Tang PP
    Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
    Senderowicz AM
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1229-53. PubMed ID: 12512390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging cell cycle inhibitors for acute myeloid leukemia.
    Abou Zahr A; Borthakur G
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):137-148. PubMed ID: 28506135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging drug profile: cyclin-dependent kinase inhibitors.
    Blachly JS; Byrd JC
    Leuk Lymphoma; 2013 Oct; 54(10):2133-43. PubMed ID: 23488658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
    Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
    Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.